Diagnostic and prognostic significance of FOXA1 expression in molecular subtypes of breast invasive ductal carcinomas

National Medical Journal of China

Volumn 90, Issue 20, 2010, Pages 1403-1407

  Liu, Ning ^a   Niu, Yun ^a   Wang, Shu Ling ^a   Yu, Qi ^a   Zhang, Rong Ju ^a   Liu, Tie Ju ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast carcinoma; FOXA1; Molecular subtype; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; FOXA1 PROTEIN, HUMAN; ISOPROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; PROTEIN EXPRESSION; ADULT; AGED; BREAST TUMOR; FEMALE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MIDDLE AGED; PROGNOSIS; PROTEIN ISOFORMS;

EID: 84871415336     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.20.011     Document Type: Article

References (20)

1. Badve S, Turbin D, Thorat M A, et al. F0XA1 expression in breast cancer-correlation with luminal subtype A and survival. Clin Cancer Res, 2007, 13:4415-4421.
2. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003, 100:8418-8423.
3. Nakshatri H, Badve S. FOXA1 as a therapeutic target for breast cancer. Expert Opin Ther Targets. 2007, 11:507-514.
4. Tavassoli F A, Devilee P. The WHO classification of tumors of the breast and female genital organs (M). Editors IARC Press, Lyon. 2003:10-112.
5. Habashy H O, Powe D G, Rakha E A, et al. Forkhead-box Al (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer, 2008, 44:1541-1551.
6. Thorat M A, Marchio C, Morimiya A, et al. Forkhead box Al expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol, 2008, 61:327-332.
7. Wolf A C, Hammond M E, Schwartz J N, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendation for human epidermal growth factor 2 testing in breast cancer. Arch Pathol Lab Med, 2007, 131: 18-43.
8. Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours. Nature, 2000, 406: 747-752.
9. Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10: 5367-5374.
10. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007, 9: R16.
11. Dylan V Miller, Alexey A Leontovich, Wilma L Lingle, et al. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Modern Pathology, 2004, 17:756-764.
12. 2009, 38: 13-17.
13. Doane A S, Danso M, Lal M P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene, 2006, 25: 3994-4008.
14. Wolf I, Bose S, Williamson E A, et al. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer, 2007, 120: 1013-1022.
15. Carroll J S, Liu X S, Brodsky A S, et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FOXA1. Cell, 2005, 122: 33-43.
16. Laganiere J, Deblois G, Lefebvre C, et al. Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A, 2005, 102: 11651-11656.
17. Hu Z, Fan C, Oh D S, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics, 2006, 7:96.
18. Kun Yu, Chee How Lee, Puay Hoon Tan, et al. A molecular signature of the nottingham prognostic index in breast cancer. Cancer Research, 2004, 64: 2962-2968.
19. 2006, 86: 862-864.
20. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol, 2005, 23:7721-7735.